Where FDA Is Paying The Most Attention: Drug Safety Advisory Committee Had The Most Meetings In 2010

FDA’s ongoing efforts to ramp up its focus on drug safety are being borne out at the advisory committee level, which saw a doubling in the number of meeting days for the Drug Safety and Risk Management Advisory Committee in 2010.